Overview

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Phase:
Phase 2
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
GW Pharmaceuticals Ltd.
United States Department of Defense